NEW YORK, Nov. 29, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company’s senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Inspire, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/inspire-medical- ...

Core Viewpoint - Saxena White P.A. has initiated a securities fraud class action lawsuit against WPP plc and certain executives, alleging misrepresentation of the company's transformation strategy and its impact on business performance during the class period from February 22, 2024, to July 8, 2025 [1][2][6]. Group 1: Class Action Details - The class action expands the allegations from a related lawsuit, extending the class period for WPP ADR purchasers [2]. - Investors wishing to serve as lead plaintiff must file a motion by December 8, 2025, as per the Private Securities Litigation Reform Act [3]. Group 2: Company Overview - WPP provides a range of services including advertising, media management, consultancy, and public relations, and has undergone a strategic transformation since becoming the world's largest advertising company in 2020 [4]. - The company rebranded its media division to WPP Media in May 2025, aiming to simplify operations and enhance strategic synergies [4]. Group 3: Allegations Against WPP - The lawsuit claims that WPP misrepresented its transformation strategy, stating that it lacked a coherent plan and faced significant internal disruptions that hindered new business generation and led to the loss of major clients [5][6]. - Positive statements made by WPP regarding its business prospects were allegedly false and misleading, lacking a reasonable basis [6]. Group 4: Impact of the Allegations - The truth about WPP's struggles was revealed on July 9, 2025, when the company admitted to disappointing results due to lower new business, resulting in an 18% drop in ADR price [7].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by certain officers and directors of Enovix Corp, urging shareholders to take action promptly due to possible limited time to enforce their rights [1]. Group 1: Legal Rights and Options - Long-term shareholders of Enovix may seek corporate governance reforms, return of funds, court-approved financial incentives, or other benefits [2]. - The law firm operates on a contingent fee basis, meaning shareholders would not incur out-of-pocket legal fees or expenses [2]. Group 2: Importance of Shareholder Participation - Shareholder involvement is crucial for improving company policies, practices, and oversight, which can lead to enhanced shareholder value [3]. Group 3: Firm's Background and Achievements - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Viewpoint - Halper Sadeh LLC is investigating potential breaches of fiduciary duties by officers and directors of Globe Life Inc., which may affect shareholder rights and corporate governance [1][2]. Group 1: Shareholder Rights and Legal Options - Long-term shareholders of Globe Life Inc. may seek corporate governance reforms, recovery of funds, court-approved financial incentives, or other benefits [2]. - Shareholder involvement is crucial for improving company policies and practices, leading to enhanced transparency and accountability, which can ultimately increase shareholder value [3]. Group 2: Firm's Background and Services - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors [4].

Core Viewpoint - Telix Pharmaceuticals Ltd. is facing a securities class action lawsuit due to regulatory setbacks and significant stock declines, particularly following critical disclosures regarding its manufacturing and supply chain processes [1][4]. Allegations and Events - The lawsuit alleges that Telix and its executives made false and misleading statements about the company's business, inflating its valuation before the truth was revealed [2][3]. - Key allegations include overstated therapeutic progress for prostate cancer candidates TLX591 and TLX592, and misrepresentation of the stability and regulatory compliance of its third-party supply chain [5]. - The lawsuit identifies two major events that led to a sharp decline in Telix's stock price: 1. A subpoena from the SEC on July 22, 2025, which caused a more than 13% drop in stock price over two trading sessions [5]. 2. A Complete Response Letter from the FDA on August 28, 2025, rejecting the Biologics License Application for TLX250-CDx, leading to a further decline of over 21% in stock price [5][4]. Investigation - Hagens Berman is investigating the claims against Telix, focusing on discrepancies between the company's assurances and the regulatory revelations that followed [6].

Company Overview - Alexandria Real Estate Equities, Inc. (NYSE:ARE) is a significant entity in the real estate investment trust (REIT) sector, specializing in the ownership, operation, and development of life science and technology campuses [1] - The company is strategically located in key urban innovation clusters, competing with firms like Boston Properties and Healthpeak Properties [1] Stock Performance - The current stock price of ARE is $53.84, reflecting a slight increase of 0.49% or $0.27, with fluctuations between $53.40 and $54.45 during the trading day [3] - Over the past year, ARE's stock has experienced a high of $111.51 and a low of $48.66, indicating notable volatility [3] - The company's market capitalization is approximately $9.3 billion, with a trading volume of 490,628 shares on the NYSE [3] Analyst Outlook - Evercore ISI has set a price target of $72 for ARE, suggesting a potential price increase of about 33.74% from its current price [2][5] - This optimistic outlook persists despite a class action lawsuit alleging securities fraud against the company, which could influence investor sentiment [2][4][5] Legal Challenges - The class action lawsuit initiated by the Rosen Law Firm targets investors who purchased ARE securities between January 27, 2025, and October 27, 2025, alleging securities fraud [2][4] - The ongoing legal proceedings may impact investor sentiment and stock performance, but the price target from Evercore ISI indicates confidence in ARE's growth potential [4][5]

Why: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of securities of Alexandria Real Estate Equities, Inc. (NYSE: ARE) between January 27, 2025 and October 27, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 26, 2026. So what: If you purchased Alexandria Real Estate Equities securities during the Class Period yo ...

Core Viewpoint - A class action lawsuit has been filed against Synopsys, Inc. for securities fraud, following a significant drop in stock price due to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - Investors have until December 30, 2025, to request to lead the case in the U.S. District Court for the Northern District of California [3]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. Group 2: Company Performance - Synopsys provides design automation software, with its Design IP segment growing from 25% of revenue in 2022 to 31% in 2024 [4]. - The company reported Q3 2025 revenue for its Design IP segment at $425.9 million, a 7.7% decline year-over-year, and net income of $242.5 million, a 43% year-over-year decline [6]. Group 3: Market Reaction - Following the release of disappointing Q3 2025 results, Synopsys stock fell nearly 36%, from $604.37 per share to $387.78 per share [6]. - The decline was attributed to customers requiring more customization for IP components, impacting the business model and economics of the Design IP segment [5][6].

INSP CLASS REMINDER: Inspire Medical Systems, Inc. Investors with Losses are Reminded to Contact BFA Law before the Imminent January 5 Securities Class Action DeadlineNovember 28, 2025 8:18 AM EST | Source: Bleichmar Fonti & AuldNew York, New York--(Newsfile Corp. - November 28, 2025) - Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) and certain of the Company's senior executives for ...

Core Viewpoint - A class action lawsuit has been filed against Stride, Inc. for securities fraud, following significant stock drops attributed to alleged violations of federal securities laws [1][3]. Company Overview - Stride, Inc. is an education technology company that provides an online platform for students across the U.S. [4]. Allegations and Stock Impact - The lawsuit claims that Stride inflated enrollment numbers by retaining "ghost students" to secure state funding and ignored compliance requirements, leading to poor customer experiences and higher withdrawal rates [4][5]. - Following the filing of the complaint on September 14, 2025, Stride's stock dropped by $18.60 per share, or over 11%, from $158.36 to $139.76 [5]. - On October 28, 2025, Stride acknowledged that poor customer experiences led to an estimated 10,000-15,000 fewer enrollments, resulting in a further stock drop of $83.48 per share, or more than 54%, from $153.53 to $70.05 [6]. Legal Proceedings - Investors have until January 12, 2026, to request to lead the case in the U.S. District Court for the Eastern District of Virginia [3]. - The lawsuit is titled MacMahon v. Stride, Inc., et al., No. 1:25-cv-02019 [3]. Investor Actions - Investors are encouraged to submit their information to the law firm representing the class action, with no upfront costs for shareholders [8].